Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects
NCT02844790Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of insulin degludec + insulin aspart in diabetes mellitus (DM), sponsored by Novo Nordisk. Primary endpoints: Area under the serum insulin degludec concentration-time curve and Area under the serum insulin aspart concentration-time curve. Started Jul 2016; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02844790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844790.